KOREA WHO
-
-
Chairman of Mezzion Pharma
Park Dong-hyun
Former Wall Street Financier Takes on New Drug Development, Nears FDA Approval for Single-Ventricle Treatment
-
Last Updated on Oct 4, 2024
-
Chairman of Mezzion Pharma
Copy Url : https://www.koreawho.com/profile/ParkDonghyun- Life Summary
Park Dong-hyun is the CEO, Chairman, and Board Chair of Mezzion Pharma.
He was born on August 15, 1956.
He graduated from Yale University with a degree in economics and earned a master's degree in accounting from New York University Graduate School.
He holds the American Institute of Certified Public Accountants (AICPA) certification.
After serving as CEO of Philcom Communication, he transitioned to the U.S. investment bank Merrill Lynch, where he worked as Vice President of Merrill Lynch Capital Markets in charge of Asia.
He then became President and CEO of Far East Investment Limited while also serving as an outside director at Dong-A Pharmaceutical.
In 2002, he was appointed CEO of Dong-A PharmTech, a new drug development company under Dong-A Pharmaceutical.
He is focused on developing ‘Udenafil,’ a drug patented by Dong-A Pharmaceutical for erectile dysfunction treatment, as a treatment for single-ventricle heart disease patients.
He is currently making his third attempt to obtain FDA approval for Udenafil.
#ParkDonghyun #MezzionPharma #YaleUniversity #FDAapproval #DongAPharmaceutical #Udenafil #singleventricle #investmentbanking #pharmaceuticalindustry #newdrugdevelopment
He was born on August 15, 1956.
He graduated from Yale University with a degree in economics and earned a master's degree in accounting from New York University Graduate School.
He holds the American Institute of Certified Public Accountants (AICPA) certification.
After serving as CEO of Philcom Communication, he transitioned to the U.S. investment bank Merrill Lynch, where he worked as Vice President of Merrill Lynch Capital Markets in charge of Asia.
He then became President and CEO of Far East Investment Limited while also serving as an outside director at Dong-A Pharmaceutical.
In 2002, he was appointed CEO of Dong-A PharmTech, a new drug development company under Dong-A Pharmaceutical.
He is focused on developing ‘Udenafil,’ a drug patented by Dong-A Pharmaceutical for erectile dysfunction treatment, as a treatment for single-ventricle heart disease patients.
He is currently making his third attempt to obtain FDA approval for Udenafil.
#ParkDonghyun #MezzionPharma #YaleUniversity #FDAapproval #DongAPharmaceutical #Udenafil #singleventricle #investmentbanking #pharmaceuticalindustry #newdrugdevelopment
- Life Summary
- Career Highlights & Challenges
- · Mezzion's Governance Structure
- · Udenafil FDA Approval Delays Lead to Continued Operating Losses
- · Third Attempt for FDA Approval of Udenafil
- · Explanation of Udenafil’s U.S. FDA Phase 3 Clinical Trial at Shareholder Meeting
- · Udenafil EU SME Designation Initiative
- · Udenafil Receives Approval for Additional Phase 3 Clinical Trials from Korean MFDS
- · From Wall Street Financier to New Drug Developer
- · History of Mezzion
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Additional Information
- Notable Quotations
- Infographic & Photos